<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00025454</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000068963</org_study_id>
    <secondary_id>U01CA062505</secondary_id>
    <secondary_id>P30CA033572</secondary_id>
    <secondary_id>CHNMC-PHI-33</secondary_id>
    <secondary_id>NCI-4751</secondary_id>
    <nct_id>NCT00025454</nct_id>
  </id_info>
  <brief_title>R115777 in Treating Patients With Advanced Solid Tumors</brief_title>
  <official_title>Phase I Trial of R115777 (NSA 702818) in Advanced Malignant Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>City of Hope Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>City of Hope Medical Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness of R115777 in treating patients who have&#xD;
      advanced solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the maximum tolerated dose of R115777 in patients with advanced malignant&#xD;
           solid tumors.&#xD;
&#xD;
        -  Assess the toxicity of this drug in these patients.&#xD;
&#xD;
        -  Determine, preliminarily, the efficacy of this drug in these patients.&#xD;
&#xD;
        -  Determine the potential predictors of response in patients treated with drug.&#xD;
&#xD;
      OUTLINE: This is a multicenter, dose-escalation study.&#xD;
&#xD;
      Patients receive oral R115777 twice daily on weeks 1 and 3. Treatment repeats every 28 days&#xD;
      in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of R115777 until the maximum tolerated dose&#xD;
      (MTD) is determined. The MTD is defined as the dose preceding that at which at least 2 of 3&#xD;
      or 2 of 6 patients experience dose-limiting toxicity.&#xD;
&#xD;
      PROJECTED ACCRUAL: A minimum of 20 patients will be accrued for this study within 12 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2001</start_date>
  <completion_date type="Actual">July 2008</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tipifarnib</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed malignant tumors deemed to be incurable or refractory to&#xD;
             therapy&#xD;
&#xD;
               -  Advanced, recurrent, or metastatic disease&#xD;
&#xD;
          -  Previously treated with at least 1 chemotherapy regimen&#xD;
&#xD;
          -  Brain metastases allowed if asymptomatic and controlled (e.g., after prior surgical&#xD;
             resection or radiotherapy/radiosurgery) and not on steroids or anticonvulsants&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Karnofsky 60-100%&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  WBC at least 3,500/mm3&#xD;
&#xD;
          -  Absolute granulocyte count at least 1,500/mm3&#xD;
&#xD;
          -  Platelet count at least 75,000/mm3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 2.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  SGOT no greater than 2.5 times ULN&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine clearance at least 60 mL/min OR&#xD;
&#xD;
          -  Creatinine no greater than 1.6 mg/dL&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 3 months after study&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  No concurrent biologic therapy&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy (6 weeks for mitomycin or nitrosourea)&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No concurrent hormonal therapy&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy and recovered&#xD;
&#xD;
          -  No prior radiotherapy to a field containing a measurable target lesion unless there is&#xD;
             evidence of progression or a new lesion is present&#xD;
&#xD;
          -  No concurrent radiotherapy to measurable lesions&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 3 weeks since prior major surgery and recovered&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  At least 2 weeks since prior proton pump inhibitors (e.g., omeprazole)&#xD;
&#xD;
          -  Concurrent H2 blockers (e.g., cimetidine or related drugs) or antacids are allowed if&#xD;
             there is an interval of at least 2 hours between H2 blocker/antacid intake and R115777&#xD;
             dosing&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Primo N. Lara, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of California, Davis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>City of Hope Comprehensive Cancer Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010-3000</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>USC/Norris Comprehensive Cancer Center and Hospital</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033-0804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City of Hope Medical Group</name>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <zip>91105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California Davis Cancer Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Lara PN Jr, Law LY, Wright JJ, Frankel P, Twardowski P, Lenz HJ, Lau DH, Kawaguchi T, Gumerlock PH, Doroshow JH, Gandara DR. Intermittent dosing of the farnesyl transferase inhibitor tipifarnib (R115777) in advanced malignant solid tumors: a phase I California Cancer Consortium Trial. Anticancer Drugs. 2005 Mar;16(3):317-21.</citation>
    <PMID>15711184</PMID>
  </results_reference>
  <verification_date>February 2010</verification_date>
  <study_first_submitted>October 11, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>February 5, 2010</last_update_submitted>
  <last_update_submitted_qc>February 5, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 8, 2010</last_update_posted>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tipifarnib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

